Bristol-Myers Squibb cites FDA monograph review in defending Excedrin safety.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS CITES OTC MONOGRAPH REVIEW IN SUPPORT OF EXCEDRIN SAFETY in responding to a position paper presented by the National Kidney Foundation at an OTC "feedback" meeting in Rockville, Md. on March 8. In a prepared statement delivered at the meeting, Bristol-Myers Squibb Executive Medical Director-Worldwide Consumer Medicines Howard Hoffman, MD, alluded to FDA's recently completed review of caffeine as an analgesic adjuvant when he said the agency has "corroborated" the company's position that Excedrin and combination analgesics are safe.